Treatment with Radiopharmaceuticals and Radionuclides in Breast Cancer: Current Options

Radiopharmaceutical therapy (RPT) is an effective and safe treatment for many types of cancer. RPT acts by binding radioactive atoms to tumor-associated antigens, monoclonal antibodies, nanoparticles, peptides, and small molecules. These treatments ensure that a concentrated dose is delivered to the targeted tumor tissue while preserving the normal tissues surrounding the tumor. Given these features, RPT is superior to traditional methods. This review article aimed to performa comprehensive review and evaluation of the potential of radionuclides and radiopharmaceuticals used in breast cancer treatment in preclinical studies conducted in the last five years

Radiopharmaceuticals developed for Zr-89-Immuno-PET

The development of molecular imaging agents used for imaging of cancer tissue is of great importance for the early detection of cancer. Positron emission tomography (PET) radiopharmaceuticals consists of a positron-emitting radionuclide and a molecularstructure. Zr-89-labeled monoclonal antibodies (mAbs), peptides, nanoparticles, proteins, and other compounds are called Zr-89-Immuno-PET and are used in cancer tissue imaging. This review provides a general overview of the potential of molecules labeled with Zr-89 radionuclide, which is chosen due to its long half-life, in preclinical and clinical studies. In light of these studies, radiopharmaceuticals created using nanoparticles have greater potential than those using antibodies